Webinars-BioDuro-Global CRDMO, Rooted in Science

UPCOMING WEBINAR

Regulatory Shifts Ahead: Preparing for FDA Changes and EU Pharmaceutical Reform

Regulatory change is underway on two fronts. FDA review practice has evolved meaningfully over recent review cycles, and the EU has finalized a sweeping reform of its pharmaceutical legislation that has not yet entered into force. For sponsors filing an IND with the FDA, preparing an EMA submission, or planning a Phase II expansion into the EU, this session offers an early look at what’s changing and how to get ahead of it.

Register Now

UPCOMING WEBINAR

Accelerating Pre-Clinical Large-Molecule Screening with an Integrated DMPK/ADME Approach

In early discovery and development, accurate bioanalytical methods, combined with CMC manufacturability, are essential for driving molecule screening and assessing developability within a DMPK/ADME framework.

Register Now

PAST WEBINARS

Accelerating Hit Discovery for Hard-to-Target Proteins: A Fragment Library Approach Applied to MyD88

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. The path from fragment hits to leads demands extensive medicinal chemistry iterations with limited guidance on the most promising directions. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated computational and experimental workflows, leaving a persistent gap between primary screening hits and lead series.

Watch Now

PAST WEBINARS

Choosing the Right Crystal: Solid Form Optimization for Pharmaceutical Development

Chemical entities can be packed in different three-dimensional arrangements through various intermolecular interactions, resulting in multiple crystalline forms with distinct properties. In pharmaceutical development, these solid forms can directly influence drug performance and intellectual property strategy, making solid-state selection a critical consideration in early-stage development.

Watch Now

PAST WEBINARS

The Art and Science of Cyclic Peptide Drug Design: From Experimental Discovery to AI-Driven Computation and the Road Ahead

Cyclic peptides have a special power in the therapeutic space — they're larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral bioavailability for demanding targets.

Watch Now

PAST WEBINARS

Accelerating ADC Discovery through Strategically Integrated Chemistry, Biology, and DMPK

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar demonstrates how integrated strategies help overcome these hurdles and support informed preclinical decisions.

Watch Now

webinars

Regulatory Shifts Ahead: Preparing for FDA Changes and EU Pharmaceutical Reform

Accelerating Pre-Clinical Large-Molecule Screening with an Integrated DMPK/ADME Approach

Accelerating Hit Discovery for Hard-to-Target Proteins: A Fragment Library Approach Applied to MyD88

Choosing the Right Crystal: Solid Form Optimization for Pharmaceutical Development

The Art and Science of Cyclic Peptide Drug Design: From Experimental Discovery to AI-Driven Computation and the Road Ahead

Accelerating ADC Discovery through Strategically Integrated Chemistry, Biology, and DMPK